Related Experiment Video
Updated: Jul 11, 2025
Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
Published on: June 20, 2025
Synthesis, molecular docking studies of formononetin derivatives as potent Bax agonists for anticancer activity
Wei-Dong Jia1, Xue Bai1,2, Qian-Qian Ma1,2
1Inner Mongolia Minzu University, Tongliao, P.R. China.
Abstract:
Formononetin as a Bax agonist exhibits anticancer effects. To identify novel Bax agonist, 18 new structurally modified formononetin derivatives were synthesised and their anticancer activities were evaluated in the A549 and Beas-2b cell lines. The results indicated that 7a elicited the most potent inhibitory effect against the A549 cell line, with an IC50 value of 0.87 μM, and no obvious toxicity to Beas-2b cells. These results indicated that 7a was 40-fold and 6.94-fold more efficacious than Formononetin and Doxorubicin, respectively. Additionally, western blot and immunofluorescence assays demonstrated that 7a downregulated the protein expression of Bcl-2 and upregulated the expressions of Bax to promote A549 apoptosis, the obtained results also suggested that 7a had the potential to be developed into a lead compound that can be applied in the prevention and treatment of lung cancer.
Insights
A novel formononetin derivative, 7a, shows potent anticancer activity against lung cancer cells by activating Bax. This compound demonstrates significant efficacy and potential for lung cancer treatment.
Area of Science:
- Medicinal Chemistry
- Molecular Biology
- Oncology
Background:
- Formononetin, a Bax agonist, exhibits anticancer properties.
- Identifying novel Bax agonists is crucial for developing new cancer therapies.
Purpose of the Study:
- To synthesize and evaluate novel formononetin derivatives as potential Bax agonists for anticancer applications.
- To assess the anticancer activity and mechanism of action of these derivatives in lung cancer cell lines.
Main Methods:
- Synthesis of 18 new formononetin derivatives.
- Anticancer activity evaluation in A549 (lung cancer) and Beas-2b (normal bronchial epithelial) cell lines.
- Western blot and immunofluorescence assays to investigate apoptosis-related protein expression (Bcl-2, Bax).
Main Results:
- Compound 7a exhibited the most potent inhibitory effect against A549 cells (IC50 = 0.87 μM), showing significantly higher efficacy than formononetin and doxorubicin.
- Compound 7a demonstrated no obvious toxicity to Beas-2b cells.
- 7a promoted A549 apoptosis by downregulating Bcl-2 and upregulating Bax protein expression.
Conclusions:
- Compound 7a is a potent Bax agonist with significant anticancer activity against lung cancer.
- 7a shows potential as a lead compound for the prevention and treatment of lung cancer.
- The mechanism involves the modulation of apoptosis-related proteins, specifically Bax and Bcl-2.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:28Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
01:15Drugs that Stabilize Microtubules